


BEOTECH SUPPORT GROUP

NuGel-HemogloBind[™]

Hemoglobin Capture Reagent From Blood and Hemolyzed Serum with NuGel™ Matrix

- Has a high degree of specificity for hemoglobin binding up to 10 mg/ml
- Removes hemoglobin from any species including human, sheep, bovine, goat, etc
- Removes hemoglobin from organs, tissues.
- Hemoglobin removal from red blood cell lysate for proteomics and biomarker drug discovery
- The flow through fractions(hemoglobin depleted) retain their enzymatic and biological activity
- The flow through fractions(hemoglobin depleted) is compatible with LC-MS, activity based protein profiling and proteomic studies.

NuGel-Hemoglobind[™] is reengineered for increased stability. It is based on NuGel silica (50 microns in size, 1000Å) covalently bound to elastomeric polyelectrolytes. It binds >95% of hemoglobin from blood.



1 Deer Park Drive, Suite M, Monmouth JCT, NJ 08852, USA• (P) 732-274-2866 • (F) 732-274-2899 • www.biotechsupportgroup.com

Supplied

Supplied

30 ml

50



BEOTECH SUPPORT GROUP

Product	Size	Total Sample Processed	Item Price	
NuGel-HemogloBind™	25 preps	500µl of blood or 5 ml of Hemolyzed Serum or Plasma	NP-HO-T25	
NuGel-HemogloBind™	50 preps	1 ml of blood or 10 ml of Hemolyzed Serum or Plasma	NP-HO-T50	
Items Required		25 Prep	50 Prep	Reage
NuGel-HemogloBind™		1.25 grams	2.5 gram	Supplie

PROTOCOL – To Treat Blood Sample Using Microfuge Tube

- 1. Weigh out 50 mg of **NuGel-HemogloBind™** matrix in a microfuge tube.
- 2. Add 200 µl of Hemoglobin Binding Buffer (HB) to the matrix. Vortex or mix well for 2 minutes at room temperature.

15 ml

25

- 3. In a separate microfuge tube, add 200 µl of **Hemoglobin Binding Buffer (HB)** and 10-20 µl of blood sample. Vortex for 3 minutes.
- 4. Add sample from step 3 to sample from step 2.

Hemoglobin Binding Buffer (HB)

SpinX Centrifuge tube filters

- 5. Vortex or mix well for 10 minutes at room temperature followed by centrifugation for 4 minutes at 10,000 rpm.
- 6. Collect the supernatant which contains hemoglobin depleted sample, while the matrix contains the hemoglobin.

PROTOCOL – To Treat Hemolyzed Plasma or Serum Sample Using Microfuge Tube

- 1. Weigh out 50 mg of **NuGel-HemogloBind™** in microfuge tube and add 400 µl Hemoglobin Binding Buffer. Vortex for 2 minute.
- 2. Add 200 µl Hemolyzed Sample to step 1.
- 3. Vortex or mix well for 10 minutes at room temperature followed by centrifugation for 4 minutes at 10,000 rpm
- 4. Collect the supernatant which contains hemoglobin depleted sample, while the matrix contains the hemoglobin.

PROTOCOL – To Treat Blood Sample Using Spin-X Tube

- 1. Weigh out 50 mg of **NuGel-HemogloBind**[™] matrix in a spin-tube.
- 2. Add 200 µl of Hemoglobin Binding Buffer. Vortex or mix well for 2 minutes at room temperature, centrifuge for 2 minutes at 10,000 rpm.
- 3. Discard the supernatant.



BEOTECH SUPPORT GROUP

- 4. In a separate microfuge tube, add 400 μl of Hemoglobin Binding Buffer to the 10-20 μl of blood sample. Vortex or shake for 3 minutes.
- 5. Add sample from step 4 to the pellet sample from step 3.
- 6. Vortex or mix well for 10 minutes at room temperature, and then centrifuge for 4 minutes at 10,000 rpm.
- 7. Collect the filtrate which contains hemoglobin depleted sample, while the matrix contains the hemoglobin.

PROTOCOL – To Treat Hemolyzed Plasma or Serum Sample Using Spin-X Tube

- Weigh out 50 mg of NuGel-HemogloBind[™] matrix in a spin-tube and add 200 µl Hemoglobin Binding Buffer. Vortex or mix well for 2 minutes at room temperature, centrifuge for 2 minutes at 10,000 rpm.
- 2. Discard supernatant.
- 3. In a separate microfuge tube, add 400 μ l Hemoglobin Binding Buffer to 200 μ l Hemolyzed sample. Vortex for 3 minutes.
- 4. Add the sample from step 3 to the pellet from step 2. Vortex or mix well for 10 minutes at room temperature followed by centrifugation for 4 minutes at 10,000 rpm
- 5. Collect the filtrate which contains hemoglobin depleted sample, while the matrix contains the hemoglobin.







How NuGel-HemogloBind[™] Works

Hemolyzed Serum or Plasma Sample

HemogloBind™



Hemoglobin bound to matrix

Flowthrough (supernatant) has serum or plasma proteins (hemoglobin depleted)

Applications for biomarker discovery, enzyme assays, toxicological studies for new drugs, protein profiling using SELDI analysis, protein array pixelation, 1D and 2D gel electrophoresis, LC-MS and MALDI-TOF MS research.

Related HemogloBind™ References

Biological Fluids

J Krupey - United States Patent: 10/180,053, 2002 <u>Removal of extraneous substances from biological</u> <u>fluids containing nucleic acids and the recovery of nucleic acids</u>

Red Cell Lysates

Kyoungsook Park, Christopher D. Saudek, and Gerald W. Hart <u>Increased Expression of β-N-Acetylglucosamindase (O-GlcNAcase) in Erythrocytes from Prediabetic and Diabetic</u> <u>Individuals</u>.Diabetes.2010;59(7):1845-50.

Stored Blood Products

Delobel J., Rubin O., Prudent M., Crettaz D., Tissot J.-D., Lion N.(2010) <u>Biomarker Analysis of Stored</u> <u>Blood Products: Emphasis on Pre-Analytical Issues</u>. International Journal of Molecular Sciences. 11(11):4601-4617

1 Deer Park Drive, Suite M, Monmouth JCT, NJ 08852, USA• (P) 732-274-2866 • (F) 732-274-2899 • www.biotechsupportgroup.com



BEOTECH SUPPORT GROUP

Red Blood Cells

Alvarez-Llamas, Gloria, Fernando de la Cuesta, Maria G. Barderas, Irene Zubiri, Maria Posada-Ayala, and Fernando Vivanco. "<u>Characterization of Membrane and Cytosolic Proteins of Erythrocytes.</u>" In Vascular Proteomics, pp. 71-80. Humana Press, 2013

Alvarez-Llamas, G., de la Cuesta, F., Barderas, M. G., Darde, V. M., Zubiri, I., Caramelo, C., Vivanco, F. <u>A</u> <u>novel methodology for the analysis of membrane and cytosolic sub-proteomes of erythrocytes by 2-</u> <u>DE.</u>Electrophoresis.2009;30:4095-4108

Zihao Wang, Kyoungsook Park, Frank Comer1, Linda C. Hsieh-Wilson, Christopher D. Saudek, Gerald W. Hart. <u>Site-Specific GlcNAcylation of Human Erythrocyte Proteins: Potential Biomarker(s) for Diabetes</u> <u>Mellitus</u>. Diabetes.2008;58, 309-317.

Datta, Pradip. <u>Effect of Hemolysis, High Bilirubin, Lipemia, Paraproteins, and System Factors on</u> <u>Therapeutic Drug Monitoring</u>. Handbook of Drug Monitoring Methods.2008; 97-109.

Yuichi Miki, Tomoki Tazawa, Kazuya Hirano, Hideki Matsushima, Shoko Kumamoto, Naotaka Hamasaki, Tomohiro Yamaguchi, Masatoshi Beppu. <u>Clearance of oxidized erythrocytes by macrophages: Involvement</u> <u>of caspases in the generation of clearance signal at band 3 glycoprotein</u>. Biochemical and Biophysical Research Communications.2007; 363(1):57-62

Sarawathi, et al., <u>Relative quantification of glycated Cu-Zn superoxide dismutase in erythrocytes by</u> <u>electrospray ionization mass spectrometry</u>, Biochimica et Biophysica Acta. 1999.1426(3):483-90

Bilirubin

Person, N.B., Effect Of HemogloBind[™] On Interference Reduction In Bilirubin Analysis.poster Clinichem, 1995.

Serum

Baion, C.M. & Ali, A.C.<u>Evaluation Of HemogloBind[™] For Removal Of O-Raffinose Crosslinked Hemoglobin</u> (Hemolink[™]) From Serum, poster AACC Meeting 1997.

Tissue

Padilla, S., Convenient Method for Decreasing the Amount of Hemoglobin in Tissue Samples Without Affecting the Level of Cholinesterase Activity, unpublished personal correspondence, 1994.

CONTACT US

We welcome your questions, comments and concerns regarding our products.

Call732-274-2866, Monday – Friday 9am-6pm EST.Fax732-274-2899Emailsales@biotechsupportgroup.comMail1 Deer Park Drive, Suite M, Monmouth JCT, NJ 08852, USA